Agomab CBO reports stock option holdings

Agomab Therapeutics NV Chief Business Officer Paul Henryk van der Horst has reported his derivative equity holdings in a Form 3.

Rhea-AI Filing Summary

Agomab Therapeutics NV Chief Business Officer Paul Henryk van der Horst has reported his derivative equity holdings in a Form 3. The filing lists several stock options to buy Agomab common shares at exercise prices of $0.0005 and $14.2600 per share.

The options cover different blocks of underlying common shares, with expiration dates ranging from 2031-03-05 through 2036-01-15. Footnotes state that some shares underlying these options are fully vested and exercisable, while others vest over time in monthly installments, subject to his continued service.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider van der Horst Paul Henryk

Role Chief Business Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 612,556 contracts (Direct)

Footnotes (5)

1. F1. The shares underlying this option are fully vested and exercisable.
2. F2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
3. F3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.
4. F4. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
5. F5. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Agomab Therapeutics (AGMB) Form 3 filing show for Paul Henryk van der Horst?

The Form 3 shows that Agomab’s Chief Business Officer holds several stock options over common shares. These options have different expiration dates and exercise prices, giving him potential future equity exposure if he chooses to exercise them.

What types of securities does Paul Henryk van der Horst report in Agomab Therapeutics (AGMB) Form 3?

He reports multiple derivative positions classified as stock options, each described as a "Stock Option (Right to Buy)" over Agomab common shares. These options provide the right, but not the obligation, to purchase common shares at preset exercise prices.

What are the exercise prices of the options reported in the Agomab Therapeutics (AGMB) Form 3?

The options have exercise prices of $0.0005 and $14.2600 per common share, reported in U.S. dollars. A footnote explains these prices reflect conversion from euros using an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

When do the stock options reported by Agomab Therapeutics (AGMB) CBO expire?

The reported stock options have expiration dates between 2031-03-05 and 2036-01-15. Each grant specifies a distinct expiration date, defining how long the Chief Business Officer has the right to exercise those options for Agomab common shares.

Are the Agomab Therapeutics (AGMB) options held by Paul Henryk van der Horst vested?

A footnote states that the shares underlying one option grant are fully vested and exercisable, while others vest over time. Additional footnotes describe vesting schedules with portions vesting initially and remaining shares vesting in equal monthly installments, contingent on continued service.

How are Agomab Therapeutics (AGMB) common shares represented in the Form 3 footnotes?

One footnote explains that Agomab’s common shares may be represented by American Depositary Shares, each currently representing one common share. This clarifies how the underlying equity can be held or traded in depositary share form in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

van der Horst Paul Henryk

(Last) (First) (Middle)

AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6

(Street)

ANTWERPEN 2600

(City) (State) (Zip)

BELGIUM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Agomab Therapeutics NV [ AGMB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	03/05/2031	Common shares(2)	114,070	$0.0005(3)	D
Stock Option (Right to Buy)	(1)	06/28/2032	Common shares(2)	45,109	$0.0005(3)	D
Stock Option (Right to Buy)	(1)	10/10/2033	Common shares(2)	124,156	$0.0005(3)	D
Stock Option (Right to Buy)	(4)	07/08/2034	Common shares(2)	5,671	$0.0005(3)	D
Stock Option (Right to Buy)	(4)	11/04/2034	Common shares(2)	143,226	$0.0005(3)	D
Stock Option (Right to Buy)	(5)	01/15/2036	Common shares(2)	180,324	$14.26(3)	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable.

2. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

3. The exercise prices are reported in U.S. dollars and reflect the conversion from EUR to USD at an exchange rate of $1.1478 per EUR 1.00 as of March 16, 2026.

4. 50% of the shares underlying this option vested on February 9, 2026, with the remainder vesting in twenty-four equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

5. 25% of the shares underlying this option shall vest on February 9, 2027, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Ellen Lefever, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)